SCI & TECH● LOWSep 8 · Sep 8, 2026, 1:27 PM
Inhibrx cancer therapy outperforms Merck’s Keytruda in mid-stage trial
Seeking Alpha Tech · global
A cancer therapy developed by Inhibrx has reportedly shown superior performance to Merck's Keytruda in a mid-stage clinical trial. This indicates a potential advancement in cancer treatment.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Sci & Tech
SCI & TECH18m agoArchaeologists are uncovering the meaning of a unique rock art siteNew ScientistSCI & TECH33m agoTelix and Ekalia to Collaborate on Astatine - 211 Production in the U . S . australiannews.net · AustraliaSCI & TECH52m agoNigeria joins league of nations in global measurement pactVanguard NigeriaSCI & TECH1h agoAfter a decade of disruption, Pattanam needs a renewed visionThe Hindu